BioMarin Pharmaceutical Inc.
BMRN
Rang în acțiuni
#1948
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market... BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
Preț acțiune
$55.77
Capitalizare de piață
$10.80B
Schimbare (1 zi)
2.01%
Schimbare (1 an)
5.09%
Țară
US
Tranzacționează BioMarin Pharmaceutical Inc. (BMRN)
Categorie
Healthcare
Raport P/E pentru BioMarin Pharmaceutical Inc. (BMRN)
Raport P/E la data de October 2026 TTM: 145.11
Conform celor mai recente rapoarte financiare și prețului acțiunilor BioMarin Pharmaceutical Inc., raportul P/E actual (TTM) este 145.11. La sfârșitul anului 2024, compania avea un P/E de 29.26.
Istoricul raportului P/E pentru BioMarin Pharmaceutical Inc. din 2000 până în 2026
Raportul P/E la sfârșitul fiecărui an
| An | Raport P/E | Schimbă |
|---|---|---|
| 2026 (TTM) | 145.11 | -62.55% |
| 2025 | 387.50 | 1,224.27% |
| 2024 | 29.26 | -72.91% |
| 2023 | 108.03 | -20.24% |
| 2022 | 135.44 | -153.72% |
| 2021 | -252.11 | -1,457.99% |
| 2020 | 18.56 | -102.92% |
| 2019 | -634.76 | 225.07% |
| 2018 | -195.27 | 46.94% |
| 2017 | -132.89 | 509.07% |
| 2016 | -21.82 | -77.64% |
| 2015 | -97.58 | -0.69% |
| 2014 | -98.26 | 78.81% |
| 2013 | -54.95 | 6.19% |
| 2012 | -51.75 | -27.73% |
| 2011 | -71.60 | -630.82% |
| 2010 | 13.49 | -100.35% |
| 2009 | -3.86K | -6,863.74% |
| 2008 | 57.14 | -126.61% |
| 2007 | -214.77 | 342.05% |
| 2006 | -48.59 | 386.32% |
| 2005 | -9.99 | 355.37% |
| 2004 | -2.19 | -65.51% |
| 2003 | -6.36 | 31.16% |
| 2002 | -4.85 | -40.63% |
| 2001 | -8.17 | -12.18% |
| 2000 | -9.30 | 0.00% |
Raportul P/E pentru companii similare sau concurenți
| Companie | P/E Ratio | Diferență P/E Ratio | Țara |
|---|---|---|---|
| 28.78 | -80.16% |
US
|
|
| -28.36 | -119.54% |
US
|
|
| -24.57 | -116.93% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -79.10% |
NL
|
Cum interpretezi un P/E ratio?
Raportul Preț/Câștig (P/E Ratio) măsoară relația dintre prețul acțiunii unei companii și câștigul pe acțiune.
Un P/E scăzut dar pozitiv indică o companie cu profituri mari în raport cu evaluarea actuală și ar putea fi subevaluată. Un P/E negativ mare (aproape de 0) indică pierderi majore.
Companiile cu un P/E peste 30 sau negativ sunt considerate în general „acțiuni de creștere”, adică investitorii se așteaptă la creștere sau profitabilitate viitoare.
Companiile cu un P/E pozitiv sub 10 sunt considerate „acțiuni de valoare”, adică sunt deja profitabile, dar cu șanse mici de creștere suplimentară.